Lexicon Pharmaceuticals, Inc. (LXRX) Stock

Understand Lexicon Pharmaceuticals, Inc.: how it makes money

Lexicon Pharmaceuticals develops and commercializes orally delivered small-molecule drugs, and it makes money from product revenue and collaboration-related licensing and milestone revenue.

The profit model is structurally dependent on future collaboration-driven licensing and milestone revenue, since the company’s product net sales metrics shown here are currently at 0.0B while multiple pipeline programs are still in clinical development.

Business quality (Weak): Clear clinical and collaboration pillars, but current reported scale appears limited (revenue shown as 0.0B and operating margin negative), so execution risk and uptake of developed assets are central to the story.

Bull case

• Sotagliflozin (INPEFA) completed Phase III clinical trials for heart failure and type 1 diabetes, which supports potential future product value and commercialization outcomes: Phase III completion for Sotagliflozin in heart failure and type 1 diabetes.
• Pipeline advancement continues in neuropathic pain, with LX9211 in Phase II clinical development: LX9211 is in Phase II clinical development for neuropathic pain.
• Collaboration and licensing agreements with major partners (Bristol-Myers Squibb and Genentech) provide a route to monetization beyond standalone sales: Strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc.
• Trial execution is in progress, with Phase Three active sites reported for the SONATA program: Sonata Phase Three Trial Active Sites is listed at 130.0.

Bear case

• Near-term profitability is challenged, with an operating margin that is negative in the latest quarter provided: Operating margin pct is -4.7 for the period ending 2026-03-31.
• The revenue base appears limited in the provided financial view, with revenue_b shown as 0.0B and product net sales metrics at 0.0 in the revenue candidates: Revenue_b is 0.0, and multiple product revenue candidates (for example, Net Product Revenue and INPEFA related net sales) are shown as 0.0.
• Adoption and commercial execution may be constrained, based on payer and access related KPIs being well below 100%: Payer Coverage is 48.0 percent and IMPEFA Access is 40.0 percent.
• Clinical development risk remains, since not all programs have reached later-stage outcomes: LX9211 is still in Phase II clinical development.

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Ocular Therapeutix, Inc. (OCUL)
• XOMA Royalty Corp. (XOMA)
• Q32 Bio Inc. (QTTB)
• Protagonist Therapeutics, Inc. (PTGX)
• Agios Pharmaceuticals, Inc. (AGIO)
• Nektar Therapeutics (NKTR)
• Aquestive Therapeutics, Inc. (AQST)
• Cumberland Pharmaceuticals Inc. (CPIX)